There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insmed (INSM – Research Report) and Castle Biosciences (CSTL – Research Report) with bullish sentiments.
Insmed (INSM)
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Insmed today and set a price target of $30.00. The company’s shares closed last Wednesday at $21.77.
According to TipRanks.com, Suvannavejh is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insmed with a $40.00 average price target, an 81.5% upside from current levels. In a report issued on July 19, Barclays also assigned a Buy rating to the stock with a $35.00 price target.
See today’s best-performing stocks on TipRanks >>
Castle Biosciences (CSTL)
Lake Street analyst Thomas Flaten maintained a Buy rating on Castle Biosciences today and set a price target of $32.00. The company’s shares closed last Wednesday at $16.79.
According to TipRanks.com, Flaten is a 4-star analyst with an average return of
Castle Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $35.38, representing an 114.2% upside. In a report issued on July 27, BTIG also assigned a Buy rating to the stock with a $30.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on INSM:
